Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
160Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $402.07B | $1.77B | $1.40 |
| 2024 | $372.81B | $4.61B | $3.66 |
| 2023 | $357.78B | $8.34B | $6.49 |
| 2022 | $322.47B | $4.31B | $3.29 |
| 2021 | $292.11B | $8.00B | $6.00 |
Social Signal Score
Earnings
Wed, Nov 4(in 3 months)
Consensus estimate $1.63 per share
Typical surprise +24.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$2.58 vs $1.87beat
- Wed, May 6$2.57 vs $2.21beat
- Tue, Feb 10$1.09 vs $1.00beat
- Wed, Oct 29$1.60 vs $1.37beat
- Thu, Jul 31$1.81 vs $1.46beat
- Thu, May 1$2.25 vs $1.70beat
Estimates and results for CVS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CVS's reported EPS growth of -30.5% a year over 4 years. Historical EPS growth of -30% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.62
- Implied price
- $35.29
- Return from $97.16
- -18.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $17.55 — -81.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 39 | 48 | 57 | 66 | 75 |
|---|---|---|---|---|---|
| -25.0% | -33.2% | -30.4% | -27.9% | -25.8% | -23.9% |
| -20.0% | -28.8% | -25.7% | -23.1% | -20.9% | -18.8% |
| -15.0% | -24.3% | -21.1% | -18.3% | -15.9% | -13.7% |
| -10.0% | -19.9% | -16.5% | -13.5% | -11.0% | -8.7% |
| -5.0% | -15.4% | -11.8% | -8.7% | -6.0% | -3.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (6)
- Newszacks.com·1d ago·Positive
Can CVS Sustain Its 2026 Recovery After Raising Earnings Guidance? CVS Health is rebuilding momentum as Aetna drives stronger profits and higher 2026 guidance, but medical costs and PBM changes could test the recovery.
View source ↗ - Newszacks.com·1d ago·Neutral
How CVS Is Building on Its Consumer-Health Care Technology Push CVS Health advances its $20 billion technology push with AI tools, Health100 and automation aimed at simplifying care and improving engagement.
View source ↗ - News (RSS)fool·2d ago·Positive
CVS Health (CVS) Q2 2026 Earnings Call Transcript Adjusted EPS surged 42.5% on margin recovery across all operating segments.
View source ↗ - Newszacks.com·4d ago·Positive
Here's Why CVS Health (CVS) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsseekingalpha.com·5d ago·Neutral
CVS Health: I Wanted A Beat And Raise, I Got It, And I'm Still At 'Hold' CVS Health Corporation's strong Q2 results delivered revenue and earnings beats while management raised operating cash flow guidance to $11.5 billion. Aetna turnaround and improved medical benefit ratios boosted first half cash generation, helping drive recent stock gains. Management anticipates higher second half medical costs alongside 2027 headwinds from 340B pricing and pharmacy drug mix shifts.
View source ↗ - News (RSS)cnbc·9d ago·Neutral
CVS blows past estimates, hikes guidance as insurance unit continues to improve CVS also announced a new collaboration with Eli Lilly that will make Zepbound and Foundayo accessible to eligible patients on the CVS Health app.
View source ↗